FDA warned Sinsin Pharmaceutical that two Korean topical pain relievers sold in the US are unapproved and misbranded drugs.
What happened
FDA reviewed the company's labeling on April 15, 2025 — the website sinsinpas.us, which sends consumers to its Amazon storefront, plus its Facebook and Instagram pages. FDA found two topical analgesic (pain-relieving rub) products sold without a prescription whose active ingredients are not allowed under the over-the-counter monograph, the rulebook that lets OTC drugs be sold without an FDA-approved application. Because they fall outside that rulebook and have no approved application, FDA calls them unapproved new drugs and misbranded drugs.
What FDA found
The two pain-relief products are 'new drugs' sold without the FDA-approved application the law requires.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a), 331(d)AREX Instant Pain Relief uses zinc oxide and mentha oil, which the OTC external analgesic monograph does not allow, alone or together.
OTC monograph M017.12, FD&C Act section 505GPain Relieving Liquid MULPAS uses chlorpheniramine maleate and thymol, which the same monograph does not allow, alone or together.
OTC monograph M017.12, FD&C Act section 505GFDA has already decided that thymol in OTC external analgesic and anesthetic products is not generally recognized as safe and effective.
21 CFR part 330; Non-Monograph Conditions NM900 (Order OTC000007)The products are misbranded because they are nonprescription drugs that do not meet the requirements for marketing under section 505G and have no approved application.
FD&C Act section 502(ee), 21 U.S.C. 352(ee)Shipping a misbranded drug into interstate commerce is prohibited.
FD&C Act section 301(a), 21 U.S.C. 331(a)
What FDA wants
FDA asks the company to write within 15 working days of receiving the letter describing the specific steps taken to fix the violations, how it will prevent them from recurring, and supporting documents. If corrections cannot be finished in that time, the company must explain the delay and give a completion date.
Who should pay attention
- US marketplaces and retailers listing foreign OTC topical drugs
- importers and distributors of Korean consumer health products
- brands that rely on the OTC monograph to sell topical analgesics without approval
This is a summary. Read the original letter on fda.gov.